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Antimicrobial activityAbstract In an endeavor to ﬁnd a new class of antimicrobial agents, a series of 2-(1H-benzimidazol-
2-yl)-5-(diethylamino)phenol, 2-(1,3-benzoxazol-2-yl)-5-(diethylamino)phenol, 2-(1,3-benzothiazol-
2-yl)-5-(diethylamino)phenol and their derivatives were synthesized starting from p-N,N-diethyl
amino salicylaldehyde with different substituted o-phenylenediamine or o-aminophenol or o-amino-
thiophenol. The newly synthesized compounds were characterized by FT-IR, 1H NMR and LC–MS
analysis. All compounds were evaluated for in vitro antibacterial activities against Escherichia coli
and Staphylococcus aureus strains and in vitro antifungal activity against Candida albicans and
Aspergillus niger strains by using serial dilution method. The antibacterial activities were expressed
as the minimum inhibitory concentration (MIC) in lg/mL.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The design of new compounds to deal with resistant bacteria
and fungi has become one of the most important areas ofantibacterial and antifungal research today, since resistance
of pathogenic bacteria and fungi toward available antimicro-
bial drug is rapidly becoming a major problem worldwide. So
the discovery of novel and potent antibacterial as well as anti-
fungal agent is more demanding and challenging for chemists
and pharmacists nowadays. Molecules with benzimidazole,
benzoxazole and benzothiazoles moieties are attractive targets
for synthesis since they often exhibit diverse and important bio-
logical properties. These heterocycles have shown different
pharmacological activities such as gram-positive antibacterial
agents, antibiotics, antiparasitic, anti-inﬂammatory, elastase
inhibitors, anti-stress, ulcer and anti-cancer agents (Redi
et al., 2008; Etna et al., 2009; Alper-Hayta et al., 2008; Kumar
S1126 V.S. Padalkar et al.et al., 2002), antiviral (Song et al., 2005) and antiparkinson
(Benazzou et al., 1995) properties. They have also been used
as ligands for asymmetric transformations (Figge et al.,
2002). Benzimidazole derivatives are unique and a broad-
spectrum class of antirhino/enteroviral agents such as
antihistaminic, antipyretic, anti-ulcerative (Scott et al., 2002),
antiallergic (Nakano et al., 2000) are effective against the hu-
man cytomegalovirus (HCMV) (Zhu et al., 2000), and are also
efﬁcient selective neuropeptide YY1 receptor antagonists (Zar-
rinmayeh et al., 1998). A careful literature survey has also re-
vealed many pyrazole derivatives of benzimidazole,
benzoxazole and benzothiazole to be reported as antifungal
and antibacterial agents (Gadakh et al., 2010). McKee and
Kerwin (2008) developed bis-benzoxazole natural product
analogs UK-1, MUK-1, DMUK-1 and 2-(2’-hydroxyphenyl)
benzoxazole analogs is one of the growing number of structur-
ally related secondary metabolites with interesting biological
activity Fig. 1, UK-1 and analogs display a wide spectrum of
potent anticancer activity against leukemia, lymphoma and
certain solid tumor-derived cell lines; however, this anticancer
natural product does not show antibacterial or antifungal
activity.
Although various derivatives are reported in the literature
for the synthesis and antimicrobial evaluation of benzimid-
azole, benzoxazole and benzothiazole incorporated in different
heterocyclic ring (Reddy et al., 2004; Karale et al., 2000), but
antimicrobial activities of these classes of compounds have re-
ceived little attention. However there are no reports available
describing antimicrobial activities of substituted benzimid-
azole, benzoxazole and benzothiazole. Therefore an attempt
is made here to synthesize series of benzimidazole, benzoxazole
and benzothiazole ring system, and their antimicrobial
properties have been evaluated.2. Experimental
2.1. Biological activity
All compounds were evaluated for in vitro antibacterial
activities against E. coli and Staphylococcus aureus strainsN O
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Figure 1 Structures of UK-1, MUK-1, DMUK-1and in vitro antifungal activity against Candida albicans and
Aspergillus niger strains by using serial dilution method.
2.2. General
Incubator at 35 and 37 C; pipettes of various sizes (Gilson);
sterile tips, 100, 200, 500 and 1000 lL; sterile normal saline;
sterile isosensitest agar (Southern Group Laboratory, SGL);
antibiotic solutions (Sigma–Aldrich); sterile solution of 10%
(v/v) DMSO in water (Sigma–Aldrich).
2.3. 2.3.Medium
Isosensitest medium was used throughout this assay, as it is pH
buffered. Although NCCLS (2000) recommends the use of
Mueller Hinton medium for susceptibility testing the isosensi-
test medium had comparable results for most of the tested bac-
terial strains (Koeth et al., 2000).
2.4. Preparation of the plates
Plates were prepared under aseptic conditions. A sterile 96 well
plate was labeled. A volume of 100 lL of test material in 10%
(v/v) DMSO (usually a stock concentration of 4 mg/mL) was
pipetted into the ﬁrst row of the plate. To all other wells
50 lL of nutrient broth. Serial dilutions were performed using
a multichannel pipette. Tips were discarded after use such that
each well had 50 lL of the test material in serially descending
concentrations. To each well 10 lL of resazurin indicator solu-
tion was added. Using a pipette 30 lL of 3.3 · strength isosen-
sitized broths were added to each well to ensure that the ﬁnal
volume was single strength of the nutrient broth. Finally,
10 lL of bacterial suspension (5 · 106 cfu/mL) was added to
each well to achieve a concentration of 5 · 105 cfu/mL. Each
plate was wrapped loosely with cling ﬁlm to ensure that bacte-
ria did not become dehydrated. Each plate had a set of con-
trols: a column with a broad-spectrum antibiotic as positive
control, a column with all solutions with the exception of the
test compound, and a column with all solutions with the excep-
tion of the bacterial solution adding 10 lL of nutrient broth in-
stead. The plates were prepared in triplicate, and placed in anN O
O
N
O
OH
DMUK-1
NO
O
O
OH
CH3
2-(2'-hydroxyphenyl)benzoxazole analogs.
and 2-(2-hydroxyphenyl) benzoxazole analogs.
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assessed visually. Any color changes from purple to pink or
colorless were recorded as positive. The lowest concentration
at which color change occurred was taken as the MIC value.
The average of three values was calculated and that was the
MIC for the test material and bacterial or fungal strain (Sarkar
et al., 2007).
2.5. General experimental
Commercial reagents and solvents were procured from s.d. ﬁne
chemicals (India) and were used without puriﬁcation. The re-
action was monitored by TLC using on 0.25 mm E-Merck Si-
lica Gel 60 F254 precoated plates, which were visualized with
UV light. Melting points were measured on standard melting
point apparatus from Sunder industrial product Mumbai,
and are uncorrected. The FT-IR spectra were recorded on Per-
kins–Elmer 257 spectrometer using KBr discs. 1H NMR spec-
tra were recorded on VXR 400-MHz instrument using TMS as
an internal standard.
2.5.1. Procedure for the preparation of 4-(N,N-diethyl amino)-
2-hydroxybenzaldehyde (2)
Phosphorous oxychloride (POCl3) (2.75 mL, 0.03 mol) was slo-
wely added to dimethylformamide (DMF) (3.65 mL, 0.05 mol)
at 5–10 C under stirring. To this cooled reagent 3-(N,N-diethyl
amino) phenol (1) (1.66 g, 0.01 mol) was added by dissolving it
in DMF (6 mL) under stirring and the resulting mixture was
heated at 75 C for 4 h.The reactionmixturewas cooled to room
temperature and then poured into ice water (60 mL). Reaction
mass was neutralized with sodium carbonate, brown colored
solid separated out, ﬁltered the separated product washed with
cold water, dried and crystallized from ethanol to get pure
product (m.p. 62 C) (lit. 62–64 C; Nicholas et al., 1957).
2.5.2. General procedure of preparation of 2-substituted
benzimidazole, benzoxazole and benzothiazole (3)
Phosphorus trichloride (0.33 mol) was added drop wise to a so-
lution of the p-N,N-diethyl salicylaldehyde (2) (0.33 mol) and
substituted 1,2-phenylenediamine or o-aminophenol or o-ami-
nothiophenol (0.33 mol) in ethanol (50 mL), maintaining the
temperature at 40–45 C, The mixture was heated at 60 C
for 4 h, after completion of reaction (monitored by TLC)
cooled the reaction mass at room temperature and brought
the alkaline to pH 8 with aqueous sodium bicarbonate solution
(20% w/v). Separated product was collected by ﬁltration and
crystallized from isopropyl alcohol.
2.5.3. General procedure for preparation of (4)
Palladium–carbon catalyst (10%) was added portion-wise dur-
ing 5–10 min to a hot solution of compound (3) (0.28 mmol) in
ethanol (50 mL) containing hydrazine hydrate (1.96 mmol).
The mixture was heated under reﬂux for 1 h. The hot solution
was ﬁltered through a Whatman paper to remove Pd/C and
further ﬁltrate was ﬁltered through silica gel (5 g) and the sol-
vent was evaporated. Pure product was obtained and analyzed
without further puriﬁcation (Padalkar et al., 2011).
2.5.4. Spectral data of synthesized compounds (4a–4i)
2.5.4.1. 2-(1H-Benzimidazol-2-yl)-5-(N,N-diethylamino) phe-
nol 4a. m.p.: 192 C. FT-IR (KBr): 2975, 1620, 1518, 1145,
817, 733 cm1. 1H NMR (400 MHz) (d: ppm): 1.13 (t, 6H),3.32 (q, 4H), 6.17 (s, 1H), 6.30–6.52 (d, 1H, J= 2.8 Hz),
6.98 (d, 1H, J= 8.8 Hz), 7.00 (dd, 1H, J= 8.8, 2.0 Hz)
7.57–7.59 (dd, 1H, J= 8.0, 2.4 Hz), 7.83–7.85 (ddd, 2H,
J= 8.0, 7.8, 1.8 Hz), 8.23–8.25 (dd, 1H, J= 8.0, 2.4 Hz),
12.13 (s, 1H). LC–MS: (282.3, 97.89%).
2.5.4.2. 5-(N,N-Diethylamino)-2-(5-nitro-1H-benzimidazol-2-
yl) phenol 4b. m.p.:264 C. FT-IR (KBr): 2991, 1620, 1520,
1338, 1149, 946, 817, 733 cm1. 1H NMR (400 MHz) (d:
ppm): 1.17 (t, 6H), 3.45 (q, 4H), 6.42 (d, 1H, J= 2.4 Hz),
6.53–6.55 (d, 1H, J= 8.4 Hz), 7.83–786 (dd, 1H, J= 8.8,
2.4 Hz), 8.03–8.05 (dd, 1H, J= 9.2, 0.8 Hz), 8.25–8.28 (dd,
1H, J= 10.8, 2.0 Hz), 8.50–8.55 (d, 1H, J= 2.0 Hz), 9.23 (s,
1H), 13.00 (s, 1H). LC–MS: (327.3, 95.99%).
2.5.4.3. 2-(5-Amino-1H-benzimidazol-2-yl)-5-(N,N-diethyla-
mino) phenol 4c. m.p.: 272 C. FT-IR (KBr): 3417, 3285,
2971, 1642, 1575, 1484, 1270, 1124, 1077, 784 cm1. 1H
NMR (400 MHz) (d: ppm): 1.12 (t, 6H), 3.35 (q, 4H), 5.30
(s, 1H), 6.17–6.18 (s, 2H), 6.31–6.33 (dd, 1H, J= 8.8,
2.4 Hz), 6.52–6.55 (dd, 1H, J= 8.8, 2.0 Hz), 6.69 (d, 1H,
1.6 Hz), 7.22–7.24 (dd, 1H, J= 8.4, 0.8 Hz), 7.69–7.71 (dd,
1H, J= 8.8, 1.0 Hz), 8.66 (s, 1H), 12.63 (s, 1H). LC–MS:
(297.3, 98.59%).
2.5.4.4. 2-(1,3-Benzoxazol-2-yl)-5-(N,N-diethylamino)phenol
4d. m.p.: 268 C. FT-IR (KBr): 3013, 1656, 1575, 1484, 1287,
1270, 1124, 1077, 784 cm1. 1H NMR (400 MHz) (d: ppm):
1.16 (t, 6H), 3.41 (q,4H), 5.87–5.89 (d, 1H, J= 8.8, 2.0 Hz),
6.08–6.10 (d, 1H, J= 2.2 Hz), 6.42–6.44 (d, 1H,
J= 8.8 Hz), 6.78–6.91(dd, 1H, J= 8.8, 1.8 Hz), 7.11–7.13
(dd, 1H J= 8.0, 2.2 Hz), 7.23 (ddd, 1H, J= 8.8, 8.0,
1.8 Hz), 7.59 (ddd, 1H, J= 8.8, 8.0, 1.8 Hz), 11.23 (s, 1H).
LC–MS: (283.3, 96.25%).
2.5.4.5. 5-(N,N-Diethylamino)-2-(6-nitro-1,3-benzoxazol-2-
yl)phenol 4e. m.p. 218 C. FT-IR (KBr): 2987, 1635, 1530,
1350, 1145, 1098, 847, 742 cm1. 1H NMR (400 MHz) (d:
ppm): 1.22 (t, 6H), 3.40 (q, 4H), 5.98–6.00 (d, 1H,
J= 2.2 Hz), 6.12–6.14 (dd, 1H, J= 8.0, 2.2 Hz), 6.45–6.47
(d, 1H, J= 8.8 Hz), 6.80–6.93(d, 1H, J= 8.8 Hz), 7.14–7.16
(dd, 1H, J= 8.8, 2.2 Hz), 7.26 (d, 1H, J= 2.2 Hz), 11.37 (s,
1H). LC–MS: (328.3, 97.12%).
2.5.4.6. 5-(N,N-Diethylamino)-2-(5-nitro-1,3-benzoxazol-2-
yl)phenol 4f. m.p.: 240 C decomposes. FT-IR (KBr): 2987,
1632, 1535, 1347, 1147, 1100, 845, 740 cm1. 1H NMR
(400 MHz) (d: ppm): 1.23 (t, 6H), 3.42 (q, 4H), 5.59 (d, 1H,
J= 2.4 Hz), 5.88–5.90 (d, 1H, J= 8.0 Hz), 5.98–6.00 (dd,
1H, J= 8.0, 2.4 Hz), 6.16–6.18 (dd, 1H, J= 8.8, 1.0 Hz),
6.95–7.08 (dd, 1H, J= 8.8, 2.0 Hz), 7.44 (dd, 1H, J= 2.4,
0.8 Hz), 11.77 (s, 1H). LC–MS: (328.3, 98.62%).
2.5.4.7. 2-(6-Amino-1,3-benzoxazol-2-yl)-5-(N,N-diethylami-
no)phenol 4g. m.p.: 269 C decomposes. FT-IR (KBr): 3427,
3281, 2967, 1643, 1560, 1487, 1267, 1124, 1067, 774 cm1. 1H
NMR (400 MHz) (d: ppm): 1.10 (t, 6H), 3.31 (q, 4H), 5.97
(d, 1H, J= 2.2 Hz), 6.14 (s, 2H), 6.24–6.26 (dd, 1H,
J= 8.8, 2.4 Hz), 6.59–6.61 (d, 1H, J= 8.8 Hz), 6.74 (dd,
1H, J= 8.8, 2.0 Hz), 7.27–7.29 (d, 1H, J= 2.4 Hz), 7.71–
7.73 (d, 1H, J= 8.8 Hz),12.13 (s, 1H). LC–MS: (298.3,
96.62%).
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no)phenol 4h. m.p.: 250 C decomposes. FT-IR (KBr): 3431,
3290, 3013, 1656, 1567, 1484, 1276, 1260, 1227, 1068,
780 cm1. 1H NMR (400 MHz) (d: ppm): 1.09 (t, 6H), 3.32
(q, 4H), 5.93 (d, 1H, J= 2.2 Hz), 6.21 (s, 2H), 6.23–6.25
(dd, 1H, J= 8.8, 2.4 Hz), 6.61–6.63 (d, 1H, J= 8.8 Hz),
6.74 (d, 1H, J= 2.6 Hz), 7.29–7.31 (dd, 1H, J= 8.4,
2.6 Hz), 7.69–7.71 (d, 1H, J= 8.8 Hz), 12.09 (s, 1H). LC–
MS: (298.3, 95.62%).
2.5.4.9. 2-(1,3-Benzothiazol-2-yl)-5-(N,N-diethylamino)phenol
4i. m.p.: 168 C. FT-IR (KBr): 2875, 1630, 1618, 1456, 1342,
1135, 812, 743 cm1. 1H NMR (400 MHz) (d: ppm): 1.21 (t,
6H), 3.41 (q, 4H), 6.27 (d, 1H, J= 1.8 Hz), 7.26–7.28 (dd,
1H, J= 8.0, 2.0 Hz), 7.29–7.31 (d, 1H, J= 8.8 Hz), 7.44–
7.46 (dd, 2H, J= 8.8, 2.0 Hz), 7.80–7.86 (ddd, 2H, J= 8.4,
8.0, 2.0 Hz), 12.56 (s, 1H). LC–MS: (299.4, 98.74%).3. Results and discussion
Recently, our research group became involved with a com-
prehensive program involving the synthesis of a series of
nitrogen heterocycles and their utilization in the synthesis
of heterocyclic compounds with potential applications (Gup-
ta et al., 2011; Padalkar et al., 2010, 2011). In continuation
to this program, we report herein the synthesis and antimi-
crobial activity of substituted 2-(1H-benzimidazol-2-yl)-5-
(diethylamino) phenol, 2-(1,3-benzoxazol-2-yl)-5-(diethyl-
amino) phenol and 2-(1,3-benzothiazol-2-yl)-5-(diethylamino)
phenol derivatives shown in Scheme 1. N,N-Diethyl m-amino
phenol (1) on formylation by using Vilsmeier–Haack reac-
tion with DMF:POCl3 at 60 C to yield p-N,N-diethyl amino
salicylaldehyde (2). The p-N,N-diethyl amino salicylaldehyde
on further reaction with different substituted o-phenylenedi-
amine or o-aminophenol or o-aminothiophenol in ethanol
and PCl3 at 60 C to obtain the corresponding 2-(1H-ben-OHEt2N
OH
NEt2
OH
Reagent and condition: a) DMF : POCl 3, 60
oC
1 2
NH2
HX
N
X
OHEt2N
R
X = NH, S, O X
3
R = H, NO2
a
c
c) Pd/C, NH2-NH2.H2O
Scheme 1 Synthesis of 2-substituted benzimidazole,zimidazol-2-yl)-5-(diethylamino)phenol, 2-(1,3-benzoxazol-2-
yl)-5-(diethylamino)phenol and 2-(1,3-benzothiazol-2-yl)-5-
(diethylamino)phenol derivatives 3. The compounds 3b, 3e
and 3f on reduction by using 10% Pd/C in ethanol and
hydrazine hydrate yield 4b, 4e and 4f. The synthesized com-
pounds are shown in Table 1. The purity of the compound
was conﬁrmed by TLC using precoated silica gel as a sta-
tionary phase, using appropriate solvent system as mobile
phase and visualized under UV-light as well as analyzed
via LC–MS analysis. Structures of the title compounds were
conﬁrmed by FT-IR, 1H NMR and Mass spectral studies.
Intermediate p-N,N-diethyl amino salicylaldehyde formation
is conﬁrmed by using melting points. FT-IR spectrum of
2-(1H-benzimidazol-2-yl)-5-(diethylamino) phenol, 2-(1,3-
benzoxazol-2-yl)-5-(diethylamino) phenol and 2-(1,3-ben-
zothiazol-2-yl)-5-(diethylamino)phenol derivatives (3) have
showed absence of absorption band at 1670 cm1 gave the
conformation of aldehydic functional group is converted
into corresponding benzimidazole, benzoxazole and benzo-
thiazole and in 1H NMR spectrum absence of peak at
9.90 d ppm conﬁrmed the conversion of formyl functional
group into target compound. LC–MS spectra showed an
accurate molecular ion for each title compounds.
3.1. Antimicrobial activity
All newly synthesized compounds 4a–4i were evaluated for
their in vitro antibacterial activity against E. coli and S. aureus
strains and in vitro antifungal activity against C. albicans and
A. niger strains by using serial dilution method. The minimum
inhibitory concentration (MIC) measurement determined for
compounds showed signiﬁcant growth inhibition zones using
serial dilution method. The MIC (lg/mL) values are recorded
in Fig. 2. The results mentioned in Fig. 2 indicate that, synthe-
sized compounds displayed variable inhibitory effects on the
growth of Escherichia coli and Staphylococcus aureus (bacterial
strain), Candida albicans and Aspergillus niger (fungal strain)., 65%
R
X = NH, S, O
N
X
OHEt2N
R
X = NH, S, O
3
N
X
OHEt2N
4
R
 = NH, S, O
R = H, NO2
R = H, NH2
b) PCl3/Ethanol, 60
oC, 70-83%
b
, 75oC, 95%
benzoxazole and benzothiazole compounds 4a–4i.
Table 1 Synthesized benzimidazole, benzoxazole and benzothiazole derivatives (4a–4i).
Entry Compounds Entry Compounds
4a
N
N
H
OHEt2N
4f
N
O
OHEt2N
NO2
4b
N
N
H
OHEt2N
NO2
4g
N
O
OHEt2N
NH2
4c
N
N
H
OHEt2N
NH2
4h
NH2N
O
OHEt2N
4d
N
O
OHEt2N
4i
N
S
OHEt2N
4e
N
O
OHEt2N
NO2
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against E. coli strain with 4i, 4i showed 50% less inhibitory
activity against E. coli. The compounds 4a–4c showed excellent
antibacterial activities against S. aureus strain, and 4d–4i deriv-
atives showed moderate inhibitory action. Regarding the struc-
ture–activity relationship of the novel benzimidazole,
benzoxazole and benzothiazole derivatives 4a–4i against the
tested bacteria, the results revealed that new compounds con-
tain benzimidazoles 4a, 4b and 4c that exhibited a broad spec-
trum of antibacterial proﬁle against tested organism as
compared to 2-substituted benzoxazole and benzothiazole
4d–4i. The electron donating and electron withdrawing groups
in target molecules 4a–4i do not affect the growth inhibitory
activity against tested bacterial strains.
The antifungal activity of 2-(1H-benzimidazol-2-yl)-5-
(diethylamino) phenol, 2-(1,3-benzoxazol-2-yl)-5-(diethyl-
amino) phenol and 2-(1,3-benzothiazol-2-yl)-5-(diethylamino)phenol derivatives 4a–4i, against antifungal strains (C. albicans
and A. niger) are summarized in Fig. 2. The results mentioned
in Fig. 2 showed that compound 4i shows excellent inhibitory
growth in the case of C. albicans as well as A. niger strain, as
compared to 4a–4h. Regarding the structure–activity relation-
ship of the novel benzimidazole, benzoxazole and benzothia-
zole derivatives 4a–4i against the tested antifungal strains,
the results revealed that new compounds contain benzothia-
zole that exhibited a broad spectrum of antifungal proﬁle
against tested organisms as compared to 2-substituted benzox-
azole and benzimidazole. Electron donating and electron with-
drawing groups on benzimidazole, benzoxazole and
benzothiazole do not affect the growth inhibitory activity
against tested fungal strains.
In general, most of the tested compounds revealed better
activity against the antibacterial strains (E. coli, S. aureus)
and antifungal strains (C. albicans, A. niger). It should also
Figure 2 Antibacterial and antifungal activities of newly syn-
thesized compounds indicated by MIC (lg/mL) using the modiﬁed
resazurin assay.
S1130 V.S. Padalkar et al.be noted that benzimidazole derivatives give better antibacte-
rial potential and benzothiazole derivatives possess better anti-
fungal potential.
4. Conclusion
In conclusion, we have designed and synthesized a series of no-
vel 2-substituted benzimidazole, benzoxazole and benzothia-
zole derivatives. These novel compounds were evaluated for
in vitro antibacterial activity against E. coli and S. aureus
strains as well as for antifungal activity against C. albicans
and A. niger strains using serial dilution technique. Benzimid-
azole and benzoxazole give excellent results against bacterial
strain and benzothiazole against fungal strain. All synthesized
compounds are conﬁrmed by FT-IR, 1H NMR and LC–MS
analysis. We believe the insights gained in this study would
be useful for the development of potential drug candidate de-
rived from benzimidazole, benzoxazole and benzothiazole in
the development of novel anti-infective agent.Acknowledgement
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